Long-acting insulin analogues versus NPH human insulin in type 2 diabetes. A meta-analysis

Diabetes Research and Clinical Practice

Volumn 81, Issue 2, 2008, Pages 184-189

  Monami, Matteo ^a   Marchionni, Niccolò ^a   Mannucci, Edoardo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Long acting insulin; Meta analysis; NPH insulin; Type 2 diabetes mellitus

Indexed keywords

DETEMIR; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; LONG ACTING INSULIN;

ARTICLE; BODY MASS; CLINICAL TRIAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47649100195     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.04.007     Document Type: Article

References (30)

1. Valensi P., and Cosson E. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?. Diabetes Metab. 31 (2005) 4S34-4S39
2. Peterson G.E. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr. Med. Res. Opin. 22 (2006) 2613-2619
3. Horvath K., Jeitler K., Berghold A., Ebrahim S.H., Gratzer T.W., Plank J., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2 (2007) CD005613
4. Pan C.Y., Sinnassamy P., Chung K.D., and Kim K.W. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res. Clin. Pract. 76 (2007) 111-118
5. Philis-Tsimikas A., Charpentier G., Clauson P., Ravn G.M., Roberts V.L., and Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther. 28 (2006) 1569-1581
6. Wang X.L., Lu J.M., Pan C.Y., Mu Y.M., Dou J.T., Ba J.M., et al. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. Diabetes Res. Clin. Pract. 76 (2007) 30-36
7. Yki-Jarvinen H., Juurinen L., Alvarsson M., Bystedt T., Caldwell I., Davies M., et al. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 30 (2007) 1364-1369
8. Rosenstock J., Davies M., Home P.D., Larsen J., Koenen C., and Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51 (2008) 408-416
9. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control. Clin. Trials 17 (1996) 1-12
10. Yokoyama H., Tada J., Kamikawa F., Kanno S., Yokota Y., and Kuramitsu M. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy. Diabetes Res. Clin. Pract. 73 (2006) 35-40
11. Fritsche A., Schweitzer M.A., and Haring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 138 (2003) 952-959
12. Hermansen K., Davies M., Derezinski T., Martinez R.G., Clauson P., and Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 (2006) 1269-1274
13. Haak T., Tiengo A., Draeger E., Suntum M., and Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes. Metab. 7 (2005) 56-64
14. Fonseca V., Bell D.S., Berger S., Thomson S., and Mecca T.E. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am. J. Med. Sci. 328 (2004) 274-280
15. Rosenstock J., Ahmann A.J., Colon G., Scism-Bacon J., Jiang H., and Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 31 (2008) 20-25
16. Massi B.M., Humburg E., Dressler A., and Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm. Metab. Res. 35 (2003) 189-196
17. Eliaschewitz F.G., Calvo C., Valbuena H., Ruiz M., Aschner P., Villena J., et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch. Med. Res. 37 (2006) 495-501
18. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
19. Yki-Jarvinen H., Dressler A., and Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23 (2000) 1130-1136
20. De Leewe L., Vague P., Selam J.L., Skeie S., Lang H., Draeger E., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes. Metab. 7 (2005) 73-82
21. Vague P., Selam J.L., Skeie S., De L., Elte I.J.W., Haahr H., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
22. Robertson K.J., Schoenle E., Gucev Z., Mordhorst L., Gall M.A., and Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet. Med. 24 (2007) 27-34
23. Kolendorf K., Ross G.P., Pavlic-Renar I., Perriello G., Philotheou A., Jendle J., et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet. Med. 23 (2006) 729-735
24. Home P.D., Hallgren P., Usadel K.H., Sane T., Faber J., Grill V., et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res. Clin. Pract. 71 (2006) 131-139
25. Raskin P., Allen E., Hollander P., Lewin A., Gabbay R.A., Hu P., et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28 (2005) 260-265
26. Home P.D., Rosskamp R., Forjanic-Klapproth J., and Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab. Res. Rev. 21 (2005) 545-553
27. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., and Wilson C.A. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23 (2000) 639-643
28. Schober E., Schoenle E., Van Dyk J., and Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 24 (2001) 2005-2006
29. Chatterjee S., Jarvis-Kay J., Rengarajan T., Lawrence I.G., McNally P.G., and Davies M.J. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes-the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res. Clin. Pract. 77 (2007) 215-222
30. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet. Med. 21 (2004) 1213-1220